Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMYNYSE / NASDAQHealthcareSmall cap

$32.59-$0.39 (-1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.9B
P/E
12.0x
EV / EBITDA
5.2x
Revenue
$868.5M
Net margin
18.3%
ROCE
20.4%

-2.4% over the last year

Harmony Biosciences Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-15.8%
3M
-14.4%
6M
+3.9%
1Y
-2.4%
5Y
-15.9%

52-week range

Day change -$0.39 (-1.2%) from $33 to $33 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HRMY, bought on each weekday since 2021.

News & filings

What Harmony Biosciences Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthFree cash flow was 40.1% of revenue in fiscal 2025.

Concerns (1)

  • Operating margin fell for three years, from 33.0% to 24.0%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Read moreShow less

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Sector
Healthcare
Shares outstanding
57.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.9B
P/E
12.0x
P/B
2.2x
EV / EBITDA
5.2x
EV / Sales
1.5x
P/S
2.2x
52-week high
$42.86
52-week low
$26.54

Profitability

Operating margin
24.0%
Net margin
18.3%
EBITDA margin
29.4%
ROE
18.2%
ROCE
20.4%
ROA
12.5%
Asset turnover
0.68

Growth

Revenue
$868.5M
Revenue growth, 1Y
21.5%
Revenue CAGR, 3Y
25.6%
Net profit growth, 1Y
9.1%
Free cash flow
$347.9M

Solvency

Current ratio
3.60
Debt / Equity
0.19
Debt / Assets
0.13
CFO / Net profit
2.19
Cash / Market cap
39.4%

Where the revenue went

Of every $100 of FY2025 revenue, $18 was left as net income.

Harmony Biosciences Holdings, Inc. income statement flow, FY2025
Harmony Biosciences Holdings, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$198.3M
RevenueGross profit$670.1M
Gross profitResearch and development$189.6M
Gross profitSelling, general and administrative$272.1M
Gross profitOperating income$208.5M
Operating incomePretax income$208.5M
Interest and other incomePretax income$6.6M
Pretax incomeTax and other$56.4M
Pretax incomeNet income$158.7M

Revenue and net profit

Revenue grew 21.5% in FY2025; net profit is the dashed line.

Harmony Biosciences Holdings, Inc. revenue and net profit by fiscal year
Harmony Biosciences Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$437.9M$181.5M
FY2023$582.0M$128.9M
FY2024$714.7M$145.5M
FY2025$868.5M$158.7M

Cash flows

FY2025: $348.2M from operations, $347.9M free after investment (dashed).

Harmony Biosciences Holdings, Inc. operating and free cash flow by fiscal year
Harmony Biosciences Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$144.5M$144.3M
FY2023$219.4M$219.1M
FY2024$219.8M$218.7M
FY2025$348.2M$347.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$868.5M+21.5%1Y
EBITDA
$255.0M+9.3%1Y
Net profit
$158.7M+9.1%1Y
Cash from operations
$348.2M+58.4%1Y
Free cash flow
$347.9M+59.1%1Y
Revenue CAGR, 3Y
25.6%
Net profit CAGR, 3Y
-4.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$868.5M$255.0M$158.7M$347.9M18.2%+21.5%+9.1%

Monthly returns

Month-by-month returns of HRMY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.3B
Liabilities$401.4M
Equity$870.2M
Paid-in capital$709.0M
Retained earnings$160.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HRMY highlighted.

P/E against peers

HRMY trades at 12.0x earnings against a peer median of -18.4x.

  1. Harmony Biosciences Holdings, Inc. (this company)12.0x

Not shown (no positive earnings and no EV / Sales): Trevi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Harmony Biosciences Holdings, Inc.HRMYthis company$1.9B12.0x2.2x18.2%5.2x
Trevi Therapeutics, Inc.TRVI$2.0B-46.3x10.8x-23.3%-45.9x
Iovance Biotherapeutics, Inc.IOVA$2.0B-5.0x2.8x-56.0%-5.2x
Ocular Therapeutix, Inc.OCUL$1.9B-7.2x2.9x-40.6%-5.1x
Astrana Health, Inc.ASTH$1.9B83.5x2.4x2.9%18.7x
Stoke Therapeutics, Inc.STOK$1.9B-272.5x5.3x-2.0%-95.4x
Pulse Biosciences, Inc.PLSE$1.9B-25.6x23.1x-90.2%-23.6x
Zymeworks Inc.ZYME$1.8B-22.8x6.9x-30.2%-22.4x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Peer median—-18.4x6.1x-35.4%-17.9x

Year-to-date ROI

HRMY since 1 January, against earlier years.

Historical volatility

HRMY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Harmony Biosciences Holdings, Inc. operating margin by fiscal year
Harmony Biosciences Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY202227.4%
FY202333.0%
FY202426.7%
FY202524.0%
LineFY2025
Cost of revenueCost Of Revenue$198.3M
Gross profitGross Profit$670.1M
Operating expensesOperating Expense$461.6M
Research and developmentResearch And Development$189.6M
Total expensesTotal Expenses$660.0M
Pretax incomePretax Income$215.1M

Learn while you research

Academy chapters picked for Harmony Biosciences Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing22% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →